Table 2

Tumor characteristics of evaluable patients
Disease characteristic (n = 1894) Total, n (%) CT, n (%) No CT, n (%)
Tumor dimensions (pT)
· pT1mic-pT1a-pT1b 422 (22.3%) 132 (31.3%) 290 (68.7%)
· pT1c 846 (44.7%) 515 (60.9%) 331 (39.1%)
· pT2-pT3-pT4b 626 (33.0%) 448 (71.6%) 178 (28.4%)
Axillary lymph node status (pN)
· pN0 1155 (61.0%) 502 (43.5%) 653 (56.5%)
· pN1 551 (29.1%) 422 (76.6%) 129 (23.4%)
· pN2 119 (6.3%) 106 (89.1%) 13 (10.9%)
· pN3 69 (3.6%) 65 (94.2%) 4 (5.8%)
Estrogen and Progesterone Receptor (ER/PgR)
· ER or PgR-positive (≥1%) 1619 (85.5%) 829 (51.2%) 790 (48.8%)
· ER and PgR 0% 274 (14.5%) 266 (97.1%) 8 (2.9%)
· Unknown 1 (0.1%) 0 (0.0%) 1 (100%)
Proliferative index (Ki67 or MIB-1)
· Low (≤20%) 1150 (60.7%) 499 (43.4%) 651 (56.6%)
· High (>20%) 691 (36.5%) 562 (81.3%) 129 (18.7%)
· Unknown 53 (2.8%) 34 (64.2%) 19 (35.8%)
HER2
· Positive 305 (16.1%) 269 (88.2%) 36 (11.8%)
· Negative 1463 (77.2%) 761 (52.0%) 702 (48.0%)
· Unknown 126 (6.7%) 65 (51.6%) 61 (48.4%)
Biological type
· Luminal A 923 (48.7%) 352 (38.1%) 571 (61.9%)
· Luminal B 342 (18.1%) 230 (67.3%) 112 (32.7%)
· HER2 305 (16.1%) 269 (88.2%) 36 (11.8%)
· Triple negative 165 (8.7%) 161 (97.6%) 4 (2.4%)
· Unknown 159 (8.4%) 83 (52.2%) 76 (47.8%)

Luminal A: ER or PgR ≥1% and proliferative index ≤20% and HER2-negative.

Luminal B: ER or PgR ≥1% and proliferative index >20% and HER2-negative.

HER2-positive: HER2-positive (IHC 3+, or IHC 2+ with HER2 amplified, HER2 amplified independently from IHC) independently from the values of ER, PgR, proliferative index.

Triple negative: ER and PgR both 0% and HER2 negative independently from the proliferative index.

Clavarezza et al.

Clavarezza et al. BMC Cancer 2012 12:216   doi:10.1186/1471-2407-12-216

Open Data